How to resist PI3Kδ inhibition: activate MAPK!

被引：1
作者：
Okkenhaug, Klaus [1 ]
机构：
[1] Univ Cambridge, Cambridge, England
来源：
BLOOD | 2021年 / 138卷 / 01期
关键词：
IDELALISIB; RITUXIMAB;
D O I：
10.1182/blood.2021011365
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Murali et al report that activation of the MAPK pathway can compensate for loss of PI3K signaling in patients with CLL who did not respond to treatment with idelalisib.
引用
收藏
页码：3 / 4
页数：2
相关论文
共 11 条
  • [1] Management of adverse events associated with idelalisib treatment: expert panel opinion
    Coutre, Steven E.
    Barrientos, Jacqueline C.
    Brown, Jennifer R.
    de Vos, Sven
    Furman, Richard R.
    Keating, Michael J.
    Li, Daniel
    O'Brien, Susan M.
    Pagel, John M.
    Poleski, Martin H.
    Sharman, Jeff P.
    Yao, Nai-Shun
    Zelenetz, Andrew D.
    [J]. LEUKEMIA & LYMPHOMA, 2015, 56 (10) : 2779 - 2786
  • [2] Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma
    Durandy, Anne
    Kracker, Sven
    [J]. BLOOD, 2020, 135 (09) : 638 - 643
  • [3] Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
    Furman, Richard R.
    Sharman, Jeff P.
    Coutre, Steven E.
    Cheson, Bruce D.
    Pagel, John M.
    Hillmen, Peter
    Barrientos, Jacqueline C.
    Zelenetz, Andrew D.
    Kipps, Thomas J.
    Flinn, Ian
    Ghia, Paolo
    Eradat, Herbert
    Ervin, Thomas
    Lamanna, Nicole
    Coiffier, Bertrand
    Pettitt, Andrew R.
    Ma, Shuo
    Stilgenbauer, Stephan
    Cramer, Paula
    Aiello, Maria
    Johnson, Dave M.
    Miller, Langdon L.
    Li, Daniel
    Jahn, Thomas M.
    Dansey, Roger D.
    Hallek, Michael
    O'Brien, Susan M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (11) : 997 - 1007
  • [4] Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma
    Kienle, Dirk L.
    Stilgenbauer, Stephan
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (08) : 917 - 929
  • [5] Discovery and saturation analysis of cancer genes across 21 tumour types
    Lawrence, Michael S.
    Stojanov, Petar
    Mermel, Craig H.
    Robinson, James T.
    Garraway, Levi A.
    Golub, Todd R.
    Meyerson, Matthew
    Gabriel, Stacey B.
    Lander, Eric S.
    Getz, Gad
    [J]. NATURE, 2014, 505 (7484) : 495 - +
  • [6] Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
    Long, G. V.
    Hauschild, A.
    Santinami, M.
    Atkinson, V.
    Mandala, M.
    Chiarion-Sileni, V.
    Larkin, J.
    Nyakas, M.
    Dutriaux, C.
    Haydon, A.
    Robert, C.
    Mortier, L.
    Schachter, J.
    Schadendorf, D.
    Lesimple, T.
    Plummer, R.
    Ji, R.
    Zhang, P.
    Mookerjee, B.
    Legos, J.
    Kefford, R.
    Dummer, R.
    Kirkwood, J. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19) : 1813 - 1823
  • [7] Murali I, 2021, Blood, V138, P44
  • [8] Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
    O'Brien, Susan
    Furman, Richard R.
    Coutre, Steven
    Flinn, Ian W.
    Burger, Jan A.
    Blum, Kristie
    Sharman, Jeff
    Wierda, William
    Jones, Jeffrey
    Zhao, Weiqiang
    Heerema, Nyla A.
    Johnson, Amy J.
    Luan, Ying
    James, Danelle F.
    Chu, Alvina D.
    Byrd, John C.
    [J]. BLOOD, 2018, 131 (17) : 1910 - 1919
  • [9] The PI3K Isoforms p110α and p110δ Are Essential for Pre-B Cell Receptor Signaling and B Cell Development
    Ramadani, Faruk
    Bolland, Daniel J.
    Garcon, Fabien
    Emery, Juliet L.
    Vanhaesebroeck, Bart
    Corcoran, Anne E.
    Okkenhaug, Klaus
    [J]. SCIENCE SIGNALING, 2010, 3 (134) : ra60
  • [10] Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Seymour, J. F.
    Kipps, T. J.
    Eichhorst, B.
    Hillmen, P.
    D'Rozario, J.
    Assouline, S.
    Owen, C.
    Gerecitano, J.
    Robak, T.
    De la Serna, J.
    Jaeger, U.
    Cartron, G.
    Montillo, M.
    Humerickhouse, R.
    Punnoose, E. A.
    Li, Y.
    Boyer, M.
    Humphrey, K.
    Mobasher, M.
    Kater, A. P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12) : 1107 - 1120
12